Foghorn Therapeutics Inc.
FHTX
$6.26
-$0.23-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.74M | 28.22M | 30.91M | 24.52M | 24.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.74M | 28.22M | 30.91M | 24.52M | 24.17M |
| Cost of Revenue | 78.83M | 82.10M | 85.47M | 83.93M | 88.62M |
| Gross Profit | -42.09M | -53.88M | -54.56M | -59.41M | -64.44M |
| SG&A Expenses | 26.38M | 26.89M | 27.55M | 27.11M | 27.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.21M | 108.99M | 113.02M | 111.03M | 116.04M |
| Operating Income | -68.48M | -80.77M | -82.11M | -86.52M | -91.87M |
| Income Before Tax | -64.58M | -75.32M | -74.28M | -72.12M | -75.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.58 | -75.32 | -74.28 | -72.12 | -75.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.58M | -75.32M | -74.28M | -72.12M | -75.40M |
| EBIT | -68.48M | -80.77M | -82.11M | -86.52M | -91.87M |
| EBITDA | -66.35M | -78.02M | -78.78M | -83.23M | -88.70M |
| EPS Basic | -0.98 | -1.17 | -1.18 | -1.15 | -1.20 |
| Normalized Basic EPS | -0.57 | -0.69 | -0.69 | -0.72 | -0.75 |
| EPS Diluted | -0.98 | -1.17 | -1.18 | -1.15 | -1.20 |
| Normalized Diluted EPS | -0.57 | -0.69 | -0.69 | -0.72 | -0.75 |
| Average Basic Shares Outstanding | 266.26M | 258.61M | 251.92M | 251.73M | 251.30M |
| Average Diluted Shares Outstanding | 266.26M | 258.61M | 251.92M | 251.73M | 251.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |